Pricing Log in Create free account

AIM ImmunoTech Inc. (AIM) vs Evogene Ltd. (EVGN)

AIM ImmunoTech Inc. and Evogene Ltd. are both Biotechnology companies. AIM ImmunoTech Inc. and Evogene Ltd. are of similar size ($6.1M and $6.0M). AIM ImmunoTech Inc. grew revenue faster over the last twelve months: −21.5% against −73.6%. Evogene Ltd. has the higher net margin (−547.6% vs −15,021.1%) and the higher return on invested capital (0.00% vs 0.00%). Across the 17 metrics below, Evogene Ltd. leads on 11 and AIM ImmunoTech Inc. on 6.

Valuation

Metric AIM EVGN Biotechnology median
P/E n/m n/m 10.60
P/S 28.83 2.06 9.40
P/B 0.35 0.59 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.70 0.55 0.66
EV/Sales (71.38) (3.58) 9.02
Earnings yield (2,575.37%) (325.00%) (32.88%)
Free cash flow yield (533.84%) (315.60%) (23.13%)

Profitability

Metric AIM EVGN Biotechnology median
Gross margin (23.16%) (67.59%) 68.51%
Operating margin (11,724.21%) (851.42%) 0.00%
Net margin (15,021.05%) (547.62%) 0.00%
Free cash flow margin (15,385.26%) (650.63%) 0.00%
Return on equity (2,382.30%) (100.03%) (51.96%)
Return on assets (169.28%) (38.31%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric AIM EVGN Biotechnology median
Revenue growth (TTM) (21.49%) (73.63%) 6.76%
EPS growth (last fiscal year) 72.19% 62.63% 29.88%
Revenue growth, 5-year CAGR (11.60%) 29.94% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric AIM EVGN Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 2.11 3.57 4.97
Net debt to EBITDA 0.22 1.12 1.01

Dividend

Metric AIM EVGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric AIM EVGN Biotechnology median
Market cap 6.07m 5.95m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack